# Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

> **NCT06331312** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 161 (actual)

## Conditions studied

- Polymyalgia Rheumatica

## Interventions

- **BIOLOGICAL:** Secukinumab

## Key facts

- **NCT ID:** NCT06331312
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-28
- **Primary completion:** 2028-08-22
- **Final completion:** 2028-08-22
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06331312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06331312, "Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06331312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*